[go: up one dir, main page]

AU3971700A - Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase - Google Patents

Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase

Info

Publication number
AU3971700A
AU3971700A AU39717/00A AU3971700A AU3971700A AU 3971700 A AU3971700 A AU 3971700A AU 39717/00 A AU39717/00 A AU 39717/00A AU 3971700 A AU3971700 A AU 3971700A AU 3971700 A AU3971700 A AU 3971700A
Authority
AU
Australia
Prior art keywords
cyclobutene
phosphodiesterase
inhibitors
dione derivatives
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU39717/00A
Inventor
Philippe R Bovy
Christophe Philippo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Publication of AU3971700A publication Critical patent/AU3971700A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU39717/00A 1999-04-20 2000-04-11 Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase Abandoned AU3971700A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9904944A FR2792635B1 (en) 1999-04-20 1999-04-20 CYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
FR9904944 1999-04-20
PCT/FR2000/000925 WO2000063170A1 (en) 1999-04-20 2000-04-11 Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase 5

Publications (1)

Publication Number Publication Date
AU3971700A true AU3971700A (en) 2000-11-02

Family

ID=9544619

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39717/00A Abandoned AU3971700A (en) 1999-04-20 2000-04-11 Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase

Country Status (6)

Country Link
AR (1) AR023528A1 (en)
AU (1) AU3971700A (en)
CO (1) CO5170443A1 (en)
FR (1) FR2792635B1 (en)
UY (1) UY26111A1 (en)
WO (1) WO2000063170A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
DE10058663A1 (en) * 2000-11-25 2002-05-29 Merck Patent Gmbh Use of thienopyrimidines
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
AR068509A1 (en) * 2007-09-19 2009-11-18 Jerini Ag BRADIQUININE B1 RECEIVER ANTAGOSNIST

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312210D0 (en) * 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
WO1997024334A1 (en) * 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives

Also Published As

Publication number Publication date
CO5170443A1 (en) 2002-06-27
UY26111A1 (en) 2000-12-29
AR023528A1 (en) 2002-09-04
WO2000063170A1 (en) 2000-10-26
FR2792635A1 (en) 2000-10-27
FR2792635B1 (en) 2001-06-01

Similar Documents

Publication Publication Date Title
EP1436290B8 (en) Alkyne-aryl-naphthyridin-4(1h)-0ne derivatives as type iv phosphodiesterase inhibitor
AU2001232036A1 (en) Pyrimidine derivatives as selective inhibitors of cox-2
AU2563900A (en) Quinoline derivatives as tyrosine kinase inhibitors
AU1302301A (en) Nitrogenous heterocycle derivatives
AU2002331311A1 (en) Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
AU1025899A (en) Carboline derivatives as cgmp phosphodiesterase inhibitors
AU2002358700A1 (en) Urea derivatives as vr1- antagonists
AU6117801A (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
AU4458700A (en) Uses of phenylglycine derivatives
PL355099A1 (en) Pyrrole derivatives as phosphodiesterase vii inhibitors
ZA200204510B (en) Imidazopyridine derivatives used as phosphodiesterase VII inhibitors.
AU2004200A (en) Poly(adp-ribose) polymerase inhibitors consisting of pyrimidine derivatives
PL354979A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
AU2002241211A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
AU4501199A (en) 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
PL355020A1 (en) Imidazole derivatives as phosphodiesterase vii inhibitors
AU3971700A (en) Cyclobutene-3,4-dione derivatives as inhibitors of phosphodiesterase
AU2001271948A1 (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors
AU4917000A (en) Oligohydroxyl substituted benzofuran-3-yl and pyridofuranylurea derivatives as phosphodiesterase iv inhibitors
AU5119500A (en) New tricyclic amidine derivatives as inhibitors of nitric oxide synthase
AU4021700A (en) Methods of use of beta1-integrin inhibitors
AU6792700A (en) 5-propynylpyrimidine derivatives as cytotoxic enzyme inhibitors
AU6002700A (en) Heterocyclic derivatives as inhibitors of factor xa
AU2028301A (en) Metal salts of 3-methyl-chromane or thiochromane derivatives
HK1045943A (en) Bissulfonamide derivatives as enzyme inhibitors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase